Anti-PD-1 antibodies for the treatment of B-cell lymphoma: Importance of PD-1+ T-cell subsets

OncoImmunology

Volumn 3, Issue 2, 2014, Pages

  Chu, Fuliang ^a   Neelapu, Sattva S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Clinical trial; Lymphoma; PD 1; Rituximab; T cell

Indexed keywords

PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; CANCER PATIENT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EFFECTOR CELL; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENE EXPRESSION PROFILING; HELPER CELL; HUMAN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

EID: 84899061253     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28101     Document Type: Article

References (10)

1. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690.
2. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369:134-44; PMID:23724846; http://dx.doi. org/10.1056/NEJMoa1305133.
3. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014; 15:69-77; PMID:24332512; http://dx.doi. org/10.1016/S1470-2045(13)70551-5.
4. Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-43; PMID:10963642.
5. Lee ST, Liu S, Radvanyi L, Sukhumalchandra P, Molldrem JJ, Wieder ED, Hwu P, Liu YJ, Kwak LW, Lizée G, et al. A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods 2008; 331:13-26; PMID:17959194; http://dx.doi. org/10.1016/j.jim.2007.09.006.
6. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4:127ra37; PMID:22461641; http://dx.doi. org/10.1126/scitranslmed.3003689.
7. Chung Y, Tanaka S, Chu F, Nurieva RI, Martinez GJ, Rawal S, Wang YH, Lim H, Reynolds JM, Zhou XH, et al. Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions. Nat Med 2011; 17:983-8; PMID:21785430; http://dx.doi.org/10.1038/nm.2426.
8. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 2013; 190:6681-93; PMID:23686488; http://dx.doi.org/10.4049/jimmunol.1201363.
9. Amé-Thomas P, Le Priol J, Yssel H, Caron G, Pangault C, Jean R, Martin N, Marafioti T, Gaulard P, Lamy T, et al. Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells. Leukemia 2012; 26:1053-63; PMID:22015774; http://dx.doi.org/10.1038/leu.2011.301.
10. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cellmediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107:3639-46; PMID:16403912; http://dx.doi. org/10.1182/blood-2005-08-3376.